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Traditional and emerging cardiovascular risk factors in end- function in chronic renal failure: (1) traditional (Fram-
stage renal disease. Patients with end-stage renal disease face ingham) risk factors (i.e., hypertension, dyslipidemia,
a particularly high risk of cardiovascular disease and total mor- smoking, and diabetes; (2) factors peculiar to chronictality. Part of their increased risk is due to a higher prevalence
renal failure (i.e., anemia and secondary hyperparathy-of established risk factors, such as arterial hypertension, diabe-
roidism; and (3) emerging risk factors, such as inflamma-tes, smoking, and anemia. Hypertension and diabetes have a
very high prevalence in dialysis patients and play a major role tion and hyperhomocysteinemia. Other factors that have
in their high mortality and morbidity. Hyperparathyroidism, hyp- been recently identified are sleep apnea, high sympa-
erhomocysteinemia and disordered lipid metabolism represent
thetic activity, and the accumulation of the endogenousfactors that are peculiarly altered by the uremic state. Inflamma-
inhibitor of NO synthase asymmetric dimethyl argininetory processes, high sympathetic activity, and the accumulation
of an endogenous inhibitor of NO synthase (ADMA), have (ADMA). Cardiovascular risk is particularly high in dia-
recently emerged as cardiovascular risk factors of paramount betic uremics. The issue of cardiovascular risk in diabetic
importance. Sleep apnea has been linked with nocturnal hyper- patients with chronic renal diseases has been reviewedtension and could be implicated in the high prevalence of
elsewhere [3] and will not be discussed in this review.concentric hypertrophy of the left ventricle in these patients.
The high cardiovascular risk of the uremic populationHypertension control, as well as appropriate treatment of ane-
mia and cessation of smoking, constitutes a fundamental area depends, in part, on the fact that these patients represent
of intervention in dialysis patients. It appears possible that, in a highly selected population in whom traditional risk fac-
the near future, control of chronic inflammatory processes of
tors are over-represented. However, traditional risk fac-high sympathetic activity and endothelial dysfunction will fur-
tors do not fully explain the high cardiovascular riskther help to curb the exceedingly high cardiovascular mortality
of patients on chronic dialysis treatment. observed in ESRD.
TRADITIONAL RISK FACTORS DO NOT FULLYCardiovascular morbidity and mortality in patients
EXPLAIN THE HIGH CARDIOVASCULARwith end-stage renal disease (ESRD) is a problem of
MORTALITY IN ESRDepidemic dimension [1]. In the United Stated Renal Data
In the general population individual risk can be reli-System, cardiovascular mortality is five times higher in
ably predicted by using cardiovascular risk calculators.very elderly patients (85 years) than in coeval controls
in the general population. The difference in cardiovascu- Various calculators are freely available on the Internet.
lar mortality between the dialysis population and the Some calculators are based on the risk equation of the
general population is inversely related to age, and in the Framingham Cohort, others on a equation based on indi-
younger cohorts (25 to 35 years), such differences reach vidual data of the major randomized clinical trials, such
an astonishing rate of 500 times higher [2]. as the INDANA project (INdividual Data ANalysis of
The main causes of the high cardiovascular mortality in Antihypertensive intervention trials) [4]. If we calculate,
ESRD are represented by ischemic heart disease (IHD), using the INDANA calculator, the expected death rate
stroke, heart failure, and sudden death (Fig. 1). Three of a 50-year-old man who smokes, who has had a myocar-
series of factors play an important role in vascular dam- dial infarction, and with a systolic blood pressure of
age and in alterations in left ventricular (LV) mass and 140 mm Hg and a serum cholesterol of 190 mg/dL (the
average BP and cholesterol in most dialysis centers), the
predicted risk of death due to a cardiovascular cause inKey words: cardiovascular risk, renal failure, dialysis, risk factors,
ESRD, uremia, dialysis, homocysteine, ADMA, hypertension. the following five years is 5.4%. The actual death rate
in a dialysis patient with identical risk factors is 10 times 2003 by the International Society of Nephrology
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have caused concern among renal physicians because
high blood pressure, rather than low blood pressure,
identified dialysis patients with longer survival. Yet,
these results come as no surprise because the characteris-
tics of patients being studied dictate the expected rela-
tionship between arterial pressure and risk. Thus, the
relationship is strong and direct in the McMahon meta-
analysis that selected patients without cardiovascular
complications at baseline, but is U-shaped in several
studies in patients with coronary heart disease. Given
the high prevalence of cardiovascular comorbidities in
the dialysis population, low blood pressure may be a
proxy of compromised cardiovascular conditions. The
only prospective observational study in dialysis patients
that adequately controlled for cardiac function at base-
Fig. 1. Risk factors and intermediate mechanisms implicated in the line (by measuring LV mass and function by echocardi-
high cardiovascular risk of end-stage renal disease.
ography) showed that a 10 mm Hg mean blood pressure
increase was associated with a 44% higher risk of devel-
oping congestive heart failure, and that patients with left
ventricular hypertrophy or chronic heart failure are athigher (50%). This difference in risk suggests that in
end-stage renal disease traditional risk factors account a much higher risk of mortality than patients without
these complications [8]. Heart failure lowers blood pres-only partly for the high cardiovascular mortality in these
patients. sure, and the prevalence of heart failure is very high
(about 40%) in both incident and prevalent hemodialysisWe will discuss traditional risk factors first and then
move to uremia-related and emerging risk factors. patients. Thus, low blood pressure is most often a marker
of severe cardiac disease rather than a causal risk factor
for cardiovascular mortality in these patients (reverse
TRADITIONAL RISK FACTORS
causality). Recent analyses in the Cardiovascular Risk
Hypertension Extended Evaluation (CREED) cohort have substan-
tially confirmed Foley’s study, and indicate that the sys-The role of hypertension in cardiovascular complica-
tions in dialysis patients has long been considered an tolic pressure values that minimize cardiovascular risk
are in the range between 100 and 150 mm Hg [9].issue of obvious importance. Such a contention was chal-
lenged by studies showing that low, rather than high,
Dyslipidemiablood pressure predicts mortality in the dialysis popu-
lation. In the early 1990s, an extensive meta-analysis Serum cholesterol in ESRD patients is, on average,
similar or even lower than that observed in the generalof prospective observational studies by MacMahon [5]
showed that the risk of cardiovascular events is related population. This phenomenon depends on the fact that
malnutrition is pervasive in ESRD. Observational stud-linearly to diastolic pressure in the general population,
and that such a relationship holds true in the normoten- ies in dialysis patients have shown that low, rather than
high, cholesterol is a marker of high risk in these patientssive range as well. It is important to note that patients
included in this meta-analysis had no cardiovascular [10]. These findings have been incorrectly interpreted,
indicating that hypercholesterolemia in ESRD shouldcomplications before the baseline visit. Of note, the risk
reduction associated with lower blood pressure levels in not be a target for intervention. This interpretation is
unsound because it ignores the strong evidence accumu-the MacMahon [6] meta-analysis resulted very close to
that observed in another meta-analysis dealing with anti- lated in primary and secondary prevention studies in
the general population that indicates a clear benefit ofhypertensive drug treatment. In contrast with findings
in these meta-analyses, the relationship between blood treating hypercholesterolemia. Thus, when present, hy-
percholesterolemia should be appropriately treated inpressure and risk is J- or U-shaped in several studies
in high-risk populations. In retrospective cohort studies ESRD patients. A controlled clinical trial testing the
effect of atorvastatin in diabetic-uremic patients on dial-based on large hemodialysis databases, the risk of mor-
tality is U-shaped. For example, in a study by Zager [7], ysis is currently underway (the 4D trial). It is important
to note that in this study no major side effects have beenmortality was higher among patients who were markedly
hypertensive or markedly hypotensive after dialysis, and noted in over 500 patients treated for almost three years
(C. Wanner, personal communication, 2002).lowest for those with a systolic blood pressure between
150 and 159 mm Hg. This and other subsequent studies Serum Lp(a) is raised in ESRD, and in cross-sectional
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studies it has been associated with coronary heart disease cular complications [19]. These observations are impor-
tant mostly because a very recent intervention study[11]. To date, no follow-up or longitudinal studies testing
the prediction power of Lp(a) for incident cardiovascular reported that controlling hyperphosphatemia and avoid-
ing the administration of calcium carbonate reduces thecomplications are available. Similarly, there is still no
evidence that a selective pharmacologic intervention on progression rate of vascular calcifications in the aorta
and in coronary arteries, as well [20].Lp(a) reduces the risk of cardiovascular disease. Given
the high atherogenic potential of this lipoprotein, such
studies are worth pursuing.
EMERGING RISK FACTORS
HomocysteineSmoking
Smoking is a risk factor of paramount importance. Homocysteine is a sulfur amino acid whose metabo-
lism depends on vitamin B12 and folic acid. The plasmaRecently, it has been implicated in the progression of
renal disease in patients with severe hypertension [12]. In levels of homocysteine are markedly raised in dialysis
patients, and high homocysteine levels have been associ-the Cardiovascular Risk Extended Evaluation in Dialysis
(CREED) study, as many as 118 out of 285 (41%) pa- ated with high cardiovascular morbidity in two cohort
studies [21, 22]. High-dose folate (5 to 15 mg/day) re-tients were active smokers. In a detailed echo-color
Doppler study of the carotid arteries in this cohort, smok- duces the serum concentration of homocysteine, but
there are no prospective studies showing that loweringing was a predictor of the number of atherosclerotic
plaques, independent of other risk factors [13]. serum homocysteine reduces cardiovascular morbidity
and mortality.
UREMIA-RELATED CARDIOVASCULAR C reactive protein
RISK FACTORS
Inflammation as measured by CRP is considered a
Anemia process of primary importance in the pathogenesis of
atherosclerosis and of major cardiovascular complica-Anemia has a negative impact not only on quality of
life but also on survival. Patients with severe anemia (Ht tions in the general population [23]. In dialysis patients,
CRP is a strong predictor of death and cardiovascular27%) have a risk of death 60% higher than patients
with moderate anemia (Ht 31% to 33%) [14]. Severe ane- complications [24]. Although CRP is also directly in-
volved in cardiovascular damage, its strong predictionmia is an important trigger of LVH because intervention
studies have demonstrated that correction of anemia in- power for adverse cardiovascular events depends on it
being a risk marker, rather than a causative risk factor.duces a partial regression of LVH independent of arterial
pressure [15]. The potential role of anemia on cardiovas- Factors responsible for high CRP in patients with ESRD
are not completely understood. High CRP has been re-cular risk is further emphasized by recent observations
in patients with heart failure and with modest degrees lated to increased serum levels of anti-Chlamydia anti-
bodies [25], but it is still uncertain if Chlamydia infectionof renal insufficiency [16]. On the other hand, the Normal
Hematocrit Trial [17] has shown that in patients at high contributes to atherosclerosis in dialysis patients. Dialy-
sate contamination has been proposed as a likely factor,cardiovascular risk, pursuing the ambitious goal of a
normal hematocrit (42%) may increase, rather than de- but serum CRP increases in the early phases of chronic
renal failure, well before starting chronic dialysis treat-crease, mortality. Although the interpretation of this
study is debatable, we should not aim at raising the ment. Inflammation is a modifiable risk factor. Aspirin
induced a marked decrease in the incidence rate of coro-hematocrit beyond the currently recommended target
(33% to 36%) in dialysis patients at high cardiovascular nary events in the large cohort of apparently healthy
subjects enrolled in the Physician’s Health Study [26],risk. Whether a normal hematocrit affords cardiovascu-
lar protection in patients at low risk remains to be estab- and lovastatin (a drug which lowers cholesterol and pos-
sesses anti-inflammatory properties) prevents cardiovas-lished.
cular events in patients with high CRP independent of
Hyperphosphatemia and hyperparathyroidism its effect on serum cholesterol [27].
Several mechanistic studies indicate that hyperpara-
thyroidism, hypercalcemia, and hyperphosphatemia can
OTHER EMERGING RISK FACTORS
trigger and/or amplify cardiovascular damage in dialy-
Asymmetric dimethyl arginine (ADMA) andsis patients. Observational studies demonstrated that
cardiovascular damage in ESRDmarked hyperphosphatemia (7.8 mg/dL) is associated
with increased mortality [18]. More recently, it has been NO production is reduced in patients with moderate
to severe renal failure, a phenomenon that is mainlyshown that a relatively less pronounced degree of hyper-
phosphatemia (6.5 mg/dL) predicts incident cardiovas- attributed to the accumulation of the endogenous inhibi-
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tor of NO synthase, ADMA [28]. On the other hand, it ity generates myocardial hypertrophy by mechanisms
only partly dependent on raised arterial pressure. In lineis well demonstrated that endothelial dysfunction is a
pervasive phenomenon in patients with chronic renal with observations suggesting that hypertension only in
part accounts for raised LV mass, we have recently re-diseases. This phenomenon may influence later morbid-
ity and mortality from large vessel atherosclerotic disease ported that the link between the muscular component
of LV mass (mean wall thickness) and plasma NE isand LVH.
It has been argued that it is unlikely that ADMA exerts largely independent of arterial pressure and other risk
factors [39]. Furthermore, we have also provided evidencemeaningful biologic effects at the plasma concentration
measured in vivo in humans [29]. Although there is no that high plasma norepinephrine in dialysis patients is
an important trigger for cardiovascular events [40].conclusive proof that ADMA interferes with the cardio-
vascular system in uremic man in vivo, most hemody- The cause of sympathetic overactivity in renal failure
is still poorly defined. An alteration in afferent neuralnamic studies performed so far are compatible with the
hypothesis that NO synthase inhibition is implicated in inputs in diseased kidneys is a possible culprit because
sympathetic nerve activity decreases in uremic man afterthe endothelial dysfunction of dialysis patients. Fur-
thermore, cross-sectional [30] and prospective studies bilateral nephrectomy [37]. Nocturnal hypoxemia trig-
gered by sleep apnea seems to be another likely cause.[31] have shown that plasma ADMA concentration is
strongly associated to atherosclerotic complications and Sleep apnea is very frequent in ESRD (about 30%),
and nocturnal hypoxemia has been associated with apredicts incident cardiovascular events in these patients.
Extensive atherosclerosis and LVH represent the main nocturnal increase in arterial pressure [41], concentric
hypertrophy [42], and adverse cardiovascular outcomescomponents of the high risk of uremic patients. There-
fore, the fact that ADMA is an independent, high-rank- in dialysis patients [43]. Nocturnal hypoxemia triggers
a marked increase in sympathetic activity that outlastsing correlate of carotid atherosclerosis [32] and LV con-
centric hypertrophy [33] also suggests that this substance hypoxemic episodes. Thus, it appears possible that the
high sympathetic tone in ESRD at least in part dependsis an important factor, mediating a process which may
result in important clinical sequels ranging from heart on the high frequency of sleep apnea and nocturnal hyp-
oxemia in this population. Whatever the explanation forfailure to coronary and cerebrovascular complications.
high sympathetic tone in patients with chronic renal fail-
Sympathetic overactivity and sleep apnea ure may be, this factor is clinically important because it
can be modified by using anti-adrenergic drugs. It hasPlasma norepinephrine (NE) in ESRD patients was
found to be high in most studies performed between the been shown that carvedilol reduces left ventricular vol-
ume and improves systolic function in dialysis patients1970s and the 1980s [34–36], and on the basis of these
studies, chronic renal failure was considered a situation with ventricular dilatation [44]. Since carvedilol has anti-
oxidant properties, it is difficult to establish whether thecharacterized by enhanced sympathetic activity. The in-
terpretation of plasma NE as a marker of sympathetic favorable effects of this drug depend solely on its anti-
adrenergic activity. Yet, this study pragmatically showsactivity is complex in patients with renal failure because
circulating NE represents only a small proportion of that interfering with adrenergic activity may represent
an important intervention area.the neurotransmitter amount secreted from adrenergic
nerve terminals, and because these patients display meta- Reducing cardiovascular risk in dialysis patients is an
absolute priority. At this stage we have “evidence-based”bolic alterations which may alter the plasma concentra-
tion of this substance. The undisputed standard for the options for intervention for some traditional risk factors
only. While it is almost undisputable that hypertensionassessment of sympathetic activity is microneurography.
This technique has convincingly demonstrated that sym- is a risk factor to be appropriately treated in dialysis
patients, and that those patients should stop smoking,pathetic activity in dialysis patients is increased [37], and
that this increase is even more consistent than it emerged we still don’t know whether normalizing hemoglobin in
patients without advanced cardiovascular disease mayfrom early studies based on plasma NE measurements.
Left ventricular hypertrophy is an adaptive process help to prevent cardiovascular damage. Furthermore,
there are still no intervention studies aimed at modifyingaimed at minimizing ventricular wall stress. Several fac-
tors, including hypertension and altered circadian arterial serum phosphate based on hard end points, or convincing
proof that reducing plasma homocysteine reduces car-pressure profile, may influence this process in patients
with renal diseases. The evidence that the sympathetic diovascular risk in dialysis patients. Until now, there has
been no study proving that interfering with sympatheticsystem is involved in the progression of cardiovascular
structural alterations such as left ventricular hypertrophy activity or with ADMA may reduce the cardiovascular
burden of ESRD. Presently, we should pay more atten-and arterial remodeling in the general population is now
substantial [38]. Norepinephrine promotes myocardial cell tion at systematically using available cardiovascular
treatments (e.g., anti-hypertensive drugs, aspirin, andhypertrophy in vitro; in vivo, sustained sympathetic activ-
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